EQNR323.30-4.60%
MOWI187.80-1.57%
YARA432.10+0.30%
TEL144.40+1.69%
Brent$73.75-2.61%
USD/NOK9,8084−0,34 %
EUR/NOK11,2140−0,18 %
LIVE · 14:40 UTC
RMHI.PK57

Retrieve Medical Holdings Inc

SoftwareLatest Reported

Retrieve Medical Holdings Inc has a negative equity position of $-300,160 million, indicating a significant financial distress, and a debt-to-equity ratio of -0.21, which suggests that the company is financed more by debt than equity. The company's liquidity is further strained by a current ratio of 0.0, meaning it has no current assets to cover its current liabilities. The negative operating cash flow of $-60 million indicates that the company is not generating sufficient cash from its operations to sustain its activities. The company's profitability is severely challenged, with a net income of $-42,710 million and an operating income of $-40,210 million. The return on equity of 14.23% is unusually high given the negative equity, and the return on assets of -122.03% indicates that the company is not effectively using its assets to generate profit. These metrics are far below the industry norms for a software company, suggesting a significant underperformance relative to its peers. The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of its revenue streams. However, the lack of detailed segment data implies that the company may be overly reliant on a single product or market, which could pose a concentration risk. The company's growth trajectory is uncertain, as there are no specific revenue growth projections provided in the available data. The negative operating income and net income suggest that the company is not currently in a growth phase and may be struggling to achieve profitability. The absence of detailed growth metrics makes it challenging to assess the company's future prospects. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt indicates that the company is not in a position to meet its short-term obligations without additional financing. The low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term, which could help maintain shareholder value. There are no recent events or filings mentioned in the available data that would provide insight into the company's current operations or strategic direction. The lack of recent disclosures makes it difficult to assess any material changes in the company's business or financial condition.

30-day price · RMHI.PK-0.44 (-33.8%)
Low$0.60High$1.87Close$0.87As of15 Jun, 00:00 UTC
Profile
CompanyRetrieve Medical Holdings Inc
TickerRMHI.PK
SectorTechnology
BusinessSoftware & IT Services
Industry groupSoftware & IT Services
IndustrySoftware
AI analysis

Business. Retrieve Medical Holdings Inc is a software company that provides medical software solutions, primarily generating revenue through software development and related services.

Classification. Retrieve Medical Holdings Inc is classified under the Technology sector, specifically in the Software & IT Services business sector and the Software industry, with a confidence level of 0.92.

Retrieve Medical Holdings Inc has a negative equity position of $-300,160 million, indicating a significant financial distress, and a debt-to-equity ratio of -0.21, which suggests that the company is financed more by debt than equity. The company's liquidity is further strained by a current ratio of 0.0, meaning it has no current assets to cover its current liabilities. The negative operating cash flow of $-60 million indicates that the company is not generating sufficient cash from its operations to sustain its activities. The company's profitability is severely challenged, with a net income of $-42,710 million and an operating income of $-40,210 million. The return on equity of 14.23% is unusually high given the negative equity, and the return on assets of -122.03% indicates that the company is not effectively using its assets to generate profit. These metrics are far below the industry norms for a software company, suggesting a significant underperformance relative to its peers. The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of its revenue streams. However, the lack of detailed segment data implies that the company may be overly reliant on a single product or market, which could pose a concentration risk. The company's growth trajectory is uncertain, as there are no specific revenue growth projections provided in the available data. The negative operating income and net income suggest that the company is not currently in a growth phase and may be struggling to achieve profitability. The absence of detailed growth metrics makes it challenging to assess the company's future prospects. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt indicates that the company is not in a position to meet its short-term obligations without additional financing. The low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term, which could help maintain shareholder value. There are no recent events or filings mentioned in the available data that would provide insight into the company's current operations or strategic direction. The lack of recent disclosures makes it difficult to assess any material changes in the company's business or financial condition.
Key takeaways
  • Retrieve Medical Holdings Inc is experiencing significant financial distress, with a negative equity position and a high debt-to-equity ratio.
  • The company's profitability is severely challenged, with a net loss and a negative return on assets.
  • The company's liquidity is extremely weak, as indicated by a current ratio of 0.0 and a negative operating cash flow.
  • The company's growth trajectory is uncertain, with no specific revenue growth projections provided.
  • The company's risk profile is characterized by a medium liquidity risk and a low dilution risk.
Financial snapshot
PeriodLatest reported
CurrencyUSD
Revenue
Gross profit
Operating income-$40.2k
Net income-$42.7k
R&D
SG&A
D&A
SBC
Operating cash flow-$60.00
CapEx
Free cash flow
Total assets$350.00
Total liabilities$300.5k
Total equity-$300.2k
Cash & equivalents
Long-term debt$63.0k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4-$22.8k-$28.4k
FY-3-$5.7k-$14.0k
FY-2-$5.5k-$15.0k
FY-1-$65.7k-$76.1k
FY0-$132.9k-$165.0k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$2.3k-$221.1k
FY-3$530.00-$235.1k
FY-2$410.00-$250.1k
FY-1$261.1k-$326.2k
FY0$130.3k-$491.1k
PeriodOCFCapExFCFSBC
FY-4-$43.7k
FY-3-$1.7k
FY-2-$120.00
FY-1-$14.3k
FY0-$68.5k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7-$40.2k-$42.7k
FQ-6-$16.9k-$19.2k
FQ-5-$3.7k-$6.8k
FQ-4-$50.5k-$59.4k
FQ-3-$46.6k-$54.6k
FQ-2$16.8k$8.8k
FQ-1-$52.6k-$59.9k
FQ0-$110.4k-$112.2k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$350.00-$300.2k
FQ-6$42.8k-$319.4k
FQ-5$261.1k-$326.2k
FQ-4$193.1k-$385.5k
FQ-3$180.2k-$440.1k
FQ-2$134.1k-$431.3k
FQ-1$130.3k-$491.1k
FQ0$102.5k-$603.4k
PeriodOCFCapExFCFSBC
FQ-7-$60.00
FQ-6-$120.00
FQ-5-$14.3k
FQ-4-$43.6k
FQ-3-$55.1k
FQ-2-$64.8k
FQ-1-$68.5k
FQ0-$30.9k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$300.2k
Net cash-$63.0k
Current ratio0.0
Debt/Equity-0.2
ROA-122.0%
ROE14.2%
Cash conversion0.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Software · cohort 779 companies
MetricRMHI.PKActivity
Op margin1.9% medp25 -17.3% · p75 13.3%
Net margin2.4% medp25 -16.3% · p75 12.7%
Gross margin55.8% medp25 32.4% · p75 76.0%
R&D / revenue24.3% medp25 12.6% · p75 50.3%
CapEx / revenue-3.6% medp25 -9.9% · p75 -0.9%
Debt / equity-21.0%5.4% medp25 0.2% · p75 31.9%bottom quartile
Observations
Competitor context
MSFTMicrosoftUSPeer
Derived from classification anchor Software.
Software, Software & IT Services, Technology
CRMSalesforceUSPeer
Derived from classification anchor Software.
Software, Software & IT Services, Technology
NOWServiceNowUSPeer
Derived from classification anchor Software.
Software, Software & IT Services, Technology
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 00:14 UTC#45caff89
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 05:33 UTCJob: 6e2a64ab